By Professor Adam Jaffe

Preprints

Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett LK; gilbert L; Lambert SB; Macartney K; Marshall HS; Martin AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling T, 2022, Real World Impact of 13vPCV in Preventing Invasive Pneumococcal Pneumonia in Australian Children: A National Study, http://dx.doi.org/10.2139/ssrn.4068377

Stick SM; Foti A; Ware RS; Tiddens HAWM; Clements BS; Armstrong DS; Selvadurai H; Tai A; Cooper PJ; Byrnes CA; Belessis Y; Wainwright C; Jaffe A; Robinson P; Saiman L; Sly PD, 2021, The Effect of Azithromycin on Structural Lung Disease in Infants with Cystic Fibrosis (COMBAT CF): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial, http://dx.doi.org/10.2139/ssrn.3990938

Allan KM; Zhang S; Wong SL; Capraro A; McCarron A; Skinner D; Kardia E; Zheng Y; Zhong L; Ng C-A; Bell JL; Farrow N; Umashankar B; Banks C; Herbert C; Kilian KA; Pandzic E; Vittorio O; Vandenberg JI; Lock JG; Jaffe A; Donnelley M; Parsons D; Woodworth BA; Cho D-Y; Waters SA, Gene-Corrected Basal Cells Restore CFTR In Vitro; Transplants Regenerate Epithelium in a Preclinical Sinus Model, http://dx.doi.org/10.1101/2025.07.21.666023

Dayaratne WL; Torres-Cadena R; Schmitt BP; Westrick EM; Jaffe A, Hybrid bronzes: mixed-valence organic-inorganic metal oxides as a tunable material platform, http://dx.doi.org/10.26434/chemrxiv-2023-v6h2h

Wong SL; Awatade NT; Astore MA; Allan KM; Carnell MJ; Slapetova I; Chen P-C; Capraro A; Fawcett LK; Whan RM; Griffith R; Ooi CY; Kuyucak S; Jaffe A; Waters SA, In silico and functional characterisation of an ultra-rare CFTR mutation identifies novel lasso motif interactions regulating channel gating, http://dx.doi.org/10.1101/2021.12.12.472297

Fawcett LK; Chew ZA; Schneider-Futschik EK; Allan KM; Patel HR; Jaffe A; Waters SA, INTEGRATING GENOMIC AND FUNCTIONAL TESTING TO IMPROVE CFTR MODULATOR RESPONSE PREDICTION IN CHILDREN WITH CYSTIC FIBROSIS, http://dx.doi.org/10.1101/2025.07.09.25331152

McKnight L; Schultz A; Vidic N; Palmer E; Jaffe A, Learning to make a difference for chILD: Value creation through network collaboration and team science, http://dx.doi.org/10.22541/au.166740302.29601419/v1

Wong SL; Awatade NT; Astore MA; Allan KM; Carnell MJ; Slapetova I; Chen P-C; Setiadi J; Pandzic E; Fawcett LK; Widger JR; Whan RM; Griffith R; Ooi CY; Kuyucak S; Jaffe A; Waters SA, Molecular dynamics and theratyping in airway and gut organoids reveal R352Q-CFTR conductance defect, http://dx.doi.org/10.1101/2021.08.11.456003

Hewson CK; Capraro A; Wong SL; Pandzic E; Fernando BSM; Awatade NT; Zhong L; Hart-Smith G; Whan RM; Thomas SR; Jaffe A; Bridge WJ; Waters SA, Novel antioxidant therapy with the immediate precursor to glutathione, γ-glutamylcysteine (GGC), ameliorates LPS-induced cellular stress in an in vitro cystic fibrosis model, http://dx.doi.org/10.1101/2020.05.27.119990

Sabino LR; Kaiko GE; Dorahy D; Goodsall TT; Jaffe A; Schultz A; Waters S; Cook D; Kok H; Tong K; Totterdell J; McGree J; Snelling T; Wark PA, Organoid Guided N-of-1 (ORIGIN-1) Clinical Trial: A phase 4 study to investigate if people with cystic fibrosis with rare non-F508del CFTR mutations with an in-vitro response to Elexacaftor/ Tezacaftor/ Ivacaftor have a clinically meaningful response to Elexacaftor/ Tezacaftor/ Ivacaftor versus placebo., http://dx.doi.org/10.21203/rs.3.rs-7787221/v1

Homaira N; Chan M; Owens L; Thomsen A; Gray M; Chuang S; Prentice B; Belessis Y; Islam S; Foster J; Jaffe A, Parent/carers opinions about COVID-19 vaccination for children with chronic lung diseases, http://dx.doi.org/10.22541/au.170666146.66053164/v1

Coffey MJ; van Dorst J; Pushpakumara BLDU; Halim J; Hudson J; Plush L; Christi K; Foster C; Carzino R; Zajakovski N; Appleton L; Cheney J; Wood J; Monaghan SJ; Rawlinson W; Day AS; Oliver M; Ranganathan S; Selvadurai H; Wainwright C; Thomas T; Jaffe A; Ooi CY, Probiotics and the EARly Life effects on intestinal bacteria and inflammation in children with Cystic Fibrosis (The “PEARL-CF” Study), http://dx.doi.org/10.64898/2025.12.04.25341620

Hartley NA; Pugh SM; Xu Z; Leong DC; Jaffe A; Forse AC, Quinone-functionalised carbons as new materials for electrochemical carbon dioxide capture, http://dx.doi.org/10.26434/chemrxiv-2023-ls7mc-v2

Jaffe A; Ziebel M; Halat DM; Biggins N; Murphy R; Chakarawet K; Reimer JA; Long JR, Selective, High-Temperature O2 Adsorption in Chemically Reduced, Redox-Active Iron-Pyrazolate Metal–Organic Frameworks, http://dx.doi.org/10.26434/chemrxiv.9922541.v4

Jaffe A; Ziebel M; Halat DM; Biggins N; Murphy R; Chakarawet K; Reimer JA; Long JR, Selective, High-Temperature O2 Adsorption in Chemically Reduced, Redox-Active Iron-Pyrazolate Metal–Organic Frameworks, http://dx.doi.org/10.26434/chemrxiv.9922541.v3

Jaffe A; Ziebel M; Halat DM; Biggins N; Murphy R; Chakarawet K; Reimer JA; Long JR, Selective, High-Temperature O2 Adsorption in Chemically Reduced, Redox-Active Iron-Pyrazolate Metal–Organic Frameworks, http://dx.doi.org/10.26434/chemrxiv.9922541.v2

Jaffe A; Ziebel M; Halat DM; Biggins N; Murphy R; Chakarawet K; Reimer JA; Long JR, Selective, High-Temperature O2 Adsorption in Chemically Reduced, Redox-Active Iron-Pyrazolate Metal–Organic Frameworks, http://dx.doi.org/10.26434/chemrxiv.9922541

Jaffe A; Ziebel M; Halat DM; Biggins N; Murphy R; Chakarawet K; Reimer JA; Long JR, Selective, High-Temperature O2 Adsorption in Chemically Reduced, Redox-Active Iron-Pyrazolate Metal–Organic Frameworks, http://dx.doi.org/10.26434/chemrxiv.9922541.v1

Umashankar B; Capraro A; Vijayan A; Wong SL; Nielsen BU; Zhong L; Raftery M; Allan K; Ooi CY; Sivam S; Visser S; Prentice BJ; Fawcett L; Kovacevic Z; Eliasson L; Faurholt-Jepsen D; Jaffe A; Shaw JA; Vafaee F; Waters SA, Serum Exosomal Multi-Omic Signatures Stratify Glucose Tolerance in Cystic Fibrosis and Reveal Partial Therapeutic Reprogramming by CFTR Modulators, http://dx.doi.org/10.1101/2025.07.07.25331056

Awatade NT; Wong SL; Pandzic E; Slapetova I; Capraro A; Zhong L; Turgutoglu N; Fawcett LK; Whan RM; Jaffe A; Waters SA, Significant functional differences despite morphological and molecular similarity in fully differentiated matched Conditionally Reprogrammed (CRC) and Feeder free dual SMAD inhibited expanded human nasal epithelial cells, http://dx.doi.org/10.1101/2020.05.29.120006

Singh J; Jaffe A; Schultz A; Selvadurai H, Surfactant Protein Deficiency Syndrome in Childhood Interstitial Lung Disease, http://dx.doi.org/10.22541/au.160037735.51250770

Chan C; Coffey M; Murphy C; McKay I; Abdu J; Paida K; Tam R; Wrigley-Carr H; Prentice B; Owens L; Belessis Y; Chuang S; Jaffe A; van Dorst J; Ooi CY, The Prevalence of pks+ E. coli in Cystic Fibrosis, http://dx.doi.org/10.20944/preprints202502.0874.v1

Stiboy E; Chan M; Islam MS; L GS; Lui K; Jaffe A; Homaira N, Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants, http://dx.doi.org/10.22541/au.166419726.62754781/v2

Stiboy E; Chan M; Islam MS; L GS; Lui K; Jaffe A; Homaira N, Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants, http://dx.doi.org/10.22541/au.166419726.62754781/v1

Back to profile page